Is Wharton’s jelly FDA approved?

Wharton's jelly and fda approval: a small sealed vial with a blank paper tag tied to its neck

Written by Oscar Tellez, founder of Regen Med Academy. Oscar is not a clinician. This post is education for licensed providers and is not medical advice. Last updated November 13, 2026.

No, Wharton’s jelly is not FDA approved. No product made from it is on FDA’s list of approved cellular and gene therapy products, which we checked on October 5, 2026. FDA names Wharton’s jelly among the unapproved products being marketed. It says INDs are needed to legally give those products to patients. This post covers that status, the reason for it, and the steps a product must pass to earn a license.

Is any Wharton’s jelly product FDA approved for clinical use today?

When a doctor calls me, the first thing they ask is, are stem cells legal or illegal? With Wharton’s jelly, that question comes in a new form, and it is the title of this post. So let’s answer it from FDA’s own pages.

Start with the word approved. FDA says “new drugs and biological products for people must be FDA approved before they are marketed, offered for sale, or shipped in interstate commerce,” with rare exceptions. Approval is a decision FDA makes about one product, and FDA publishes it.

Where does FDA publish those decisions for cell products? It keeps a list of approved cellular and gene therapy products. FDA marks the list as current as of September 17, 2026. We read it on October 5, 2026. No Wharton’s jelly product is on it.

That list changes, so open it on the day you need the answer. If a rep tells you a product was just approved, the list is where you check.

If the term itself is new to you, start with our post on what Wharton’s jelly is. In one line, it is the soft connective tissue of the umbilical cord. As a product, it comes from a donor.

What has FDA said about Wharton’s jelly, and when?

FDA has named it on two public pages, and both pages carry dates.

The first is a consumer alert on regenerative medicine products. It is dated July 22, 2020, and FDA marks it as current as of April 9, 2024. The alert speaks to anyone considering what it calls “widely promoted products.” Its examples include “human umbilical cord blood, Wharton’s Jelly, or amniotic fluid.”

The second is FDA’s patient and consumer page on regenerative medicine therapies, marked current as of April 8, 2024. It lists the unapproved products it means: “stem cells, stromal vascular fraction (fat-derived cells), umbilical cord blood and/or cord blood stem cells, amniotic fluid, Wharton’s jelly, ortho-biologics, and exosomes.”

What does that page say about using them? It says, “FDA has repeatedly notified manufacturers, clinics, and health care practitioners of the need for Investigational New Drug applications (INDs) to legally administer these products.” Notice who is in that sentence. Clinics and providers are named right next to the makers.

The same page also speaks straight to patients. It says “if you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally.” Your patients can read that sentence on a phone in your waiting room.

Why does FDA regulate these products as drugs and biological products?

Here is the rule first. Human cell and tissue products are called HCT/Ps, and 21 CFR 1271.10 sorts them. It says a product “is regulated solely under section 361 of the PHS Act and the regulations in this part if it meets all of the following criteria.” Then it lists four.

Here are the four in short form. The product is minimally manipulated, and it is intended for homologous use only. It is not combined with another article, apart from a few listed agents. And it either has no systemic effect and does not depend on living cells, or it fits one of three narrow cases. We walk through each one in our post on the 351 and 361 rules.

What happens to a product that misses one? 21 CFR 1271.20 answers that. It says the product “will be regulated as a drug, device, and/or biological product,” unless one of a few listed exceptions applies.

FDA’s consumer page puts the same idea in one sentence: “Those HCT/Ps that pose an additional risk because of their processing or use also require FDA approval before marketing.” Look at two words in the middle of it, processing and use.

So the reason goes beyond where the tissue came from. FDA looks at what was done to the tissue, and at what the product is sold to do.

How do the four criteria apply to a donor cord product?

We cannot rule on a product, and a rep cannot either. What the rule can do is tell you where to look, so take the four in order.

The first is about processing. FDA’s July 2020 guidance lists “Amniotic membrane and umbilical cord” among its examples of structural tissues. For structural tissue, the rule says minimal manipulation means “processing that does not alter the original relevant characteristics of the tissue relating to the tissue’s utility for reconstruction, repair, or replacement.” So ask what the processing did to the cord, and what form the product is in now.

The second is about use. The rule defines homologous use as use of a product that “performs the same basic function or functions in the recipient as in the donor.” In the donor, this tissue sat inside a cord. So ask what job the brochure gives the product, and whether the tissue had that job in the cord.

The brochure counts here. The rule reads intended use from “the labeling, advertising, or other indications of the manufacturer’s objective intent.” What a company prints about its vial is part of the test.

The third is about what is mixed in, so ask for a list of everything that was added.

The fourth matters most for donor tissue. A product that has a systemic effect, or that depends on living cells for its main function, can meet this test in three cases only. The rule names them as “autologous use,” “allogeneic use in a first-degree or second-degree blood relative,” and “reproductive use.”

A donor product meant for an unrelated patient fits none of those three. So it has to pass the other way. That way is for a product that “does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function.” If a sales sheet leads with living cells, ask the rep how that fits this test.

Remember the word all in the rule. One miss is enough to put a product on the drug and biologic side.

There is a limit to what we can show you here. The guidance does not use the words Wharton’s jelly, and FDA marks it “Contains Nonbinding Recommendations.” So read the rule as the law.

What does FDA registered mean on a brochure?

It means the company filed a form. The section that sets the four criteria also says a tissue establishment “must register with FDA” and must submit “a list of each HCT/P manufactured.” So registration is a duty, and a company meets it by filing.

Does FDA review the product before it accepts the form? The rule says it does not. 21 CFR 1271.27 reads: “FDA acceptance of an establishment registration and HCT/P listing form does not constitute a determination that an establishment is in compliance with applicable rules and regulations or that the HCT/P is licensed or approved by FDA.”

FDA’s consumer page agrees: “Mere registration of an establishment or listing of a drug or device does not denote approval of the establishment, the drug or device.”

FDA’s patient page shows that the agency knows how the word gets used. It says patients “are told that a product is registered with FDA, as a way to suggest that the products being offered are in compliance with FDA laws and regulations.” Then it says that registering and listing a product “does not mean the product is legally marketed.”

So keep the phrase FDA registered off your own website. It is true of a company’s paperwork, and it tells a patient nothing about approval.

What does a 361 claim mean, and who decides it?

A rep may tell you the product is a 361 product. What is that claim? It is the company’s own reading of the four criteria. And as our post on the 351 and 361 rules explains, meeting the four criteria is not an FDA approval either.

Has FDA agreed with the company’s reading? Registration does not tell you. FDA’s public registration database carries a notice about that. The notice says registration and listing “does not constitute a determination” that a product “is appropriately regulated solely under section 361 of the PHS Act.”

So who can decide? FDA can, and its questions and answers page for these products explains how. A company “may file a request for a recommendation with the Tissue Reference Group (TRG) or submit a Request for Designation (RFD) with the Office of Combination Products (OCP).”

That gives you a plain question for the rep. Has your company asked FDA, and may I see the answer in writing? If the answer is no, then 361 is a claim on a brochure.

FDA has also spoken to this claim out loud. On November 17, 2022, FDA’s biologics center held an online session for practitioners and posted the transcript. An official from its compliance office said, “We often see Wharton’s jelly products marketed as 361 HCT/Ps, and the same really applies to exosomes.” The next sentence in the transcript is “That is not correct.”

Those are spoken remarks, and they are not a rule. FDA’s patient page also lists Wharton’s jelly among unapproved products. So we will not call any Wharton’s jelly product a 361 product in this post.

What is the regulatory pathway to approval for a Wharton’s jelly product?

In outline it has two steps, an IND and then a biologics license. FDA’s questions and answers page says it in two sentences. “An approved BLA is required to lawfully market these products. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect.”

BLA is short for biologics license application. The sponsor is the company or person who files with FDA.

Step one is the IND. It is the filing that lets a sponsor test an unapproved product in people. It is not an approval, and FDA says so on that page: “an IND is not marketing authorization for a product.” A later post in this series is all about the IND.

Step two is the license. FDA describes the application as “a request for permission to introduce, or deliver for introduction, a biologic product into interstate commerce.” The law behind it is section 351 of the Public Health Service Act. It says a license rests on a showing that the product is “safe, pure, and potent,” and that the place where it is made meets standards too.

Who walks this path? The company that makes the product does. A clinic that buys a vial is not on the path, and a seller’s filing does not change the product’s status.

FDA is plain about the middle of the path. It says, “A product that requires but lacks premarket approval may not be lawfully marketed, including when a sponsor has an IND or is pursuing an IND or BLA.” So a filing in progress is not an approval.

We do not know when any Wharton’s jelly product will reach the end of that path, or whether one will. We will not guess.

What changed on May 31, 2021?

FDA had given the makers of some tissue products extra time. The questions and answers page says FDA announced that policy “to give manufacturers time to determine if they need to submit an IND or marketing application.”

That time ran out. The page says that after May 31, 2021, FDA “no longer intends to exercise enforcement discretion with respect to the IND and the premarket approval requirements.” In plain words, FDA had held off on enforcing those two requirements for a period, and the period is over.

The page then answers a question from a seller’s point of view. “If you market/offer for sale an HCT/P that requires premarket review as a drug and biological product, you do so at your own risk.”

FDA marks that page as current as of July 9, 2021. So if anyone tells you FDA is still giving these products time, the date on FDA’s own page says otherwise.

Does a state law change the federal status?

No. State law does not override federal law. A state can set who may perform a procedure under its own licenses. It cannot turn an unapproved product into an approved one. Approval comes from FDA.

Providers ask us, can I take any course in my state? For this subject, look at what the course is. Ours is online, and it is education only. Taking it does not change the federal status of any product, and it does not change what your license allows.

State law in this field changes, sometimes more than once a year. Our reading of each state, with its sources and the date we checked, is on the rules by state page. It is a starting point, not legal advice.

When you read your state’s entry, keep the order in mind. Federal law comes first, and no state page changes what is on FDA’s approved list.

What can a provider do today?

FDA’s questions and answers page gives you the line. It says, “You may not administer an unapproved product without an approval or IND that is in effect.” Inside that line, there is still real work to do.

  • Learn the terms and the rule. Read what Wharton’s jelly is, read the four criteria, and take the free FDA course.
  • Check FDA’s approved list yourself, and write down the date you checked.
  • Read your own website and handouts. Take out FDA registered, 361 and any wording that suggests approval.
  • Ask every vendor for its FDA status in writing, and ask what its labeling says the product is for.
  • Bring what you collect to your own attorney, and take scope questions to your licensing board.

What if a company says it has an IND? FDA tells you how to check. It says “the agency cannot disclose the existence of an IND,” so you ask the sponsor. You can confirm an IND “by obtaining from the sponsor the FDA-issued IND number as well as a copy of the official FDA communication acknowledging the IND.”

Then read what FDA says next, because it changes your role. “If you are receiving a product that has an IND in effect, then you would be considered a clinical investigator associated with the IND.” That is a research role with its own rules, so talk to your attorney before you agree to anything.

An IND is also not a pass for regular care. FDA says, “even if you have an IND in effect, the unapproved product may not be administered as a treatment outside of the IND.”

The idea of asking a vendor for answers on paper comes from Carla Mazzeo, PhD, who is on our science faculty. The exosome vendor checklist is hers, and the same idea fits here.

Where does Regen Med Academy stand on Wharton’s jelly?

Regen Med Academy is an education company. We sell education and nothing else, which means we do not sell a device or a biologic. We are not tied to any vendor, and we take no commission.

We approach Wharton’s jelly as a subject to learn, and we do not present it as a service to add. Our online Wharton’s jelly course is education only, and the wait list is the only way into it today.

The rules have their own course with us. Our free FDA legal foundations mini course takes about 45 minutes, it is self-paced, and it has five lessons.

We cannot say which rule covers a product that a rep is offering you. That answer comes from the rule, from FDA and from your own counsel. The authority on your own scope is your licensing board, not us.

Frequently asked questions

Does an IND mean a Wharton’s jelly product is approved?

No. FDA’s questions and answers page says “an IND is not marketing authorization for a product.” An IND lets a sponsor ship an unapproved product to the investigators who will test it. It does not let anyone sell the product as regular care. It also does not make any claim about the product true.

Is a listing on ClinicalTrials.gov an FDA approval?

No. FDA’s patient page says that “The inclusion of a product in the clinicaltrials.gov database” does not mean “the product is legally marketed.” A listing tells you that someone posted a study record, and it is not a decision by FDA.

Does the approval of cord blood products cover Wharton’s jelly?

No. Cord blood and Wharton’s jelly are two different products. FDA’s consumer alert was last updated in April 2024. It says the cord blood products it describes are approved “for use in patients with disorders that affect the production of blood.” It adds that “they are not approved for other uses.” For what is approved today, read FDA’s live list.

Can a Wharton’s jelly product be used off-label?

Off-label is a term for an approved product. FDA writes, “Unapproved use of an approved drug is often called ‘off-label’ use.” No Wharton’s jelly product is approved, so there is no label to step outside of. An unapproved product is a different thing from an off-label use.

Do Expanded Access or Right to Try let my clinic use it?

Both programs are real, and both are narrow. Expanded Access is for a patient with “a serious or immediately life-threatening disease or condition.” Right to Try is for patients “diagnosed with life-threatening diseases or conditions.” Neither one lets a clinic give its own product to its own patients.

Key takeaways

  • No Wharton’s jelly product is FDA approved. None was on FDA’s list of approved cellular and gene therapy products when we checked it on October 5, 2026.
  • FDA names Wharton’s jelly among the unapproved products being marketed, and it says INDs are needed to legally administer them.
  • A tissue product falls under section 361 alone only if it meets all four criteria in 21 CFR 1271.10(a). One miss puts it on the drug and biologic side.
  • FDA registered means a company filed a form. The rule says that is not a finding that a product is licensed or approved.
  • A 361 claim on a brochure is the company’s own reading until FDA says so in writing.
  • The pathway is an IND and then a biologics license. FDA says a product that lacks approval may not be lawfully marketed while a sponsor pursues either one.
  • State law does not change the federal status.

RMA disclosure

Regenerative Medicine Academy (RMA) is an education company. We train licensed providers in some of the techniques this post covers. This post is education only. It is not medical, legal, business, tax or financial advice.

We do not sell a device or a biologic, and we take no commission from any vendor.

Your next step

Open FDA’s approved list today and write down the date you checked it. Then get the free FDA course. If you want the science and the rules for this product taught in one place, join the wait list for our Wharton’s jelly course.

The course that goes with this post

FDA Legal Foundations of Regenerative Medicine

The FDA rules behind this field, in a short, self-paced course. It costs nothing.

Or see all courses

Regen Med Academy is an education company. Everything on this site is education for licensed providers, not medical or legal advice, not a treatment recommendation, and not an offer to treat. Before you offer a procedure in your state, talk to your own legal counsel and your licensing board.

Table of Contents

Prefer our take? Star us in Google.

More from the blog